Advanced Biomed Inc. (NASDAQ:ADVB – Get Free Report) saw a large increase in short interest in June. As of June 15th, there was short interest totaling 8,876 shares, an increase of 356.3% from the May 31st total of 1,945 shares. Approximately 0.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 35,930 shares, the short-interest ratio is presently 0.2 days.
Analyst Ratings Changes
Separately, Weiss Ratings raised Advanced Biomed from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Advanced Biomed presently has a consensus rating of “Sell”.
Check Out Our Latest Report on ADVB
Advanced Biomed Stock Performance
Advanced Biomed (NASDAQ:ADVB – Get Free Report) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.38) earnings per share for the quarter.
About Advanced Biomed
Our Mission We are committed to the application research of integrating semiconductor technology and biotechnology. Through the enrichment, capture, and identification of circulating tumor cells and related tumor marker cells in the field of liquid biopsy, we aim to provide cancer patients with rapid and affordable assay products and services. These services include early screening and detection, diagnosis and staging, treatment selection, and patient outcome interventions for cancer. We are a holding company incorporated in the State of Nevada.
Featured Articles
- Five stocks we like better than Advanced Biomed
- MarketBeat Week in Review – 06/22 – 06/26
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
Receive News & Ratings for Advanced Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
